SAN FRANCISCO, Nov. 06, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced a new health economic analysis of the mSToPS study, presented at the American Heart Association’s 2022 Scientific Sessions event.
The study, titled “Cost-Effectiveness of AF Screening with Two-Week Patch Monitors: The mHealth Screening to Prevent Strokes Study,” evaluated the cost-effectiveness of screening for atrial fibrillation (AFib) with Zio XT. The analysis found that systematic screening for AFib in an at-risk population with the iRhythm Zio XT patch provided high value from a health economic perspective.
Over three years, individuals prescribed Zio XT were more likely than unmonitored individuals to have outpatient visits — including to cardiologists — but less likely to require emergency department visits or hospitalization. In patient-level projections, the group prescribed Zio XT had slightly better total and quality-adjusted survival (11.91 vs. 11.82 life years, 9.38 vs. 9.30 years). The study demonstrated an incremental cost-effectiveness ratio (ICER) of $17,000 per quality-adjusted life year gained, which is the academic standard for measuring how well medical treatments lengthen and/or improve patients’ lives. The ICER is substantially lower than accepted willingness-to-pay thresholds in the U.S. and other healthcare systems. The authors concluded that screening for AFib using Zio XT provided high value from a health economic perspective.
“mSToPS is the first study to observe the benefits of AFib screening at three years — which translates to a small but meaningful gain in quality-adjusted life expectancy with a nominal (<1%) increase in lifetime healthcare spending — and the first to complete a formal health economic analysis. We conclude that AFib screening with Zio monitors is likely to both benefit older Americans and provide excellent value to the healthcare system by enabling early diagnosis,” said Dr. Matthew R. Reynolds, cardiac electrophysiologist at Lahey Hospital & Medical Center and Baim Institute for Clinical Research.
mSToPS was a landmark direct-to-participant randomized clinical trial combined with a prospective matched observational cohort study. The study, published in the Journal of the American Medical Association in 2018 and conducted at the Scripps Research Translational Institute in partnership with Aetna and Janssen Pharmaceuticals, found that Zio XT-based screening was associated with increased detection of AFib, greater use of outpatient cardiology care, and a higher rate of initiation of stroke prevention therapy. A three-year follow-up analysis of the mSToPS study, published in PLOS One in 2021, found that screening with Zio XT was associated with a lower rate of clinical events and improved outcomes relative to a matched cohort.
“Taken together, these studies demonstrate screening for AFib in at-risk populations can lead to positive patient health outcomes, especially when coupled to appropriate therapy, including stroke prevention, rhythm control, and risk factor modification,” commented Dr. Mintu Turakhia, chief medical officer and chief scientific officer at iRhythm. “These studies are not in isolation and build upon a strong body of evidence from randomized trials including STROKE-STOP, EAST-AFNET 4, and others. This is precisely why we have launched Know Your Rhythm®
To learn more about iRhythm, please visit the website.
About the “Cost-Effectiveness of AF Screening with Two-Week Patch Monitors: The mHealth Screening to Prevent Strokes Study”
Authors: Matthew R. Reynolds, MD; Amy B. Stein, PhD; Evangelos Hytopoulos, PhD; Xiaowu Sun, PhD; Steven R. Steinhubl, MD; David J. Cohen, MD
The authors conducted a health economic analysis of AFib screening with Zio ambulatory ECG monitors using patient-level data from the mSToPS study. Clinical outcomes and costs from the payer perspective were obtained from enrollment through three years using Aetna claims data. Study group participants (mean age 74 years, 41% female, median CHA2DS2-VASC score 3) wore an average of 1.7 two-week ambulatory ECG monitors at an average cost of $601/person. Over three years, individuals prescribed Zio patch monitors were more likely than unmonitored individuals to have outpatient visits, including to cardiology, but less likely to require emergency department visits or hospitalization. Pharmacy costs over three years were similar between groups. Total adjusted three-year costs, including patch monitors, were slightly higher (difference $1,170, 95% CI -1,315 to 3,657) in the monitoring group. In patient-level projections, the monitoring group had slightly better total and quality-adjusted survival (11.91 vs. 11.82 life years, 9.38 vs. 9.30 QALYs) and slightly higher lifetime costs, resulting in an incremental cost-effectiveness ratio of $16,978/QALY gained. The investigators conclude that based on lifetime projections derived from the mSToPS study, AF screening using two-week Zio XT patch monitoring provided high value from a health economic perspective.
About iRhythm Technologies, Inc.
iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Investor Relations Contact:
iRhythm Media Contact:
The content is by Globe Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.
Comments are closed.